- Home
- SPRY
as 06-20-2025 3:41pm EST
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.4B | IPO Year: | N/A |
| Target Price: | $28.75 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.55 - $18.51 | Next Earning Date: | 08-05-2025 |
| Revenue: | $97,122,000 | Revenue Growth: | 971120.00% |
| Revenue Growth (this year): | -4.28% | Revenue Growth (next year): | 140.40% |
Stock Insider Trading Activity of ARS Pharmaceuticals Inc. (SPRY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Scott Kathleen D. | SPRY | Chief Financial Officer | May 20 '25 | Sell | $14.10 | 50,000 | $705,165.00 | 7,424 | |
| Fitzpatrick Alexander A | SPRY | Chief Legal Officer | May 20 '25 | Sell | $14.10 | 102,969 | $1,451,512.81 | 89,613 | |
| SAUNDERS BRENT L | SPRY | Director | May 20 '25 | Sell | $14.25 | 120,000 | $1,710,024.00 | 0 | |
| Shawver Laura | SPRY | Director | Apr 7 '25 | Sell | $12.30 | 50,002 | $615,074.60 | 210,346 |
Latest ARS Pharmaceuticals Inc. News
SPRY Breaking Stock News: Dive into SPRY Ticker-Specific Updates for Smart Investing
Insider Monkey
6 days ago
Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”
Simply Wall St.
9 days ago
Top Growth Stocks With Strong Insider Ownership In June 2025
GlobeNewswire
25 days ago
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
Simply Wall St.
a month ago
Exploring US High Growth Tech Stocks In May 2025
Simply Wall St.
a month ago
What You Need To Know About The ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analyst Downgrade Today
GuruFocus.com
a month ago
ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Call Highlights: Strong Launch of Neffy Amid ...
Thomson Reuters StreetEvents
a month ago
Q1 2025 ARS Pharmaceuticals Inc Earnings Call
Zacks
a month ago
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates
Compare SPRY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRY ARS Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.